Helicos BioSciences (NASDAQ: HLCS) is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos's proprietary True Single Molecule Sequencing (tSMS)™, technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and committed to providing scientists the tools to unlock the era of genomic medicine. The company is currently planning the introduction of its first product, the Helicos™ Genetic Analysis System.
Based on Helicos's tSMS technology, the Helicos Genetic Analysis System enables ultra-highthroughput genetic analysis by directly sequencing single molecules of nucleic acids. The tSMS workflow is based on a simple, cost effective sample preparation process that can easily be scaled and replicated to meet the requirements of large, complex experiments, overcoming laboratory workflow bottlenecks.
Helicos believes the tSMS sequencing by synthesis approach will represent the first comprehensive and universal solution for single molecule genetic analysis, dramatically lowering the cost of individual analyses. The Helicos Genetic Analysis System will have extensive capabilities in basic and translational research, and pharmaceutical R&D, thus increasing the potential for improved drug therapies, personalized medicine and more accurate molecular diagnostics for diseases such as cancer.
Partnerships
Helicos has recently joined the Personalized Medicine Coalition, seeking to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. Read more about our partnerships.